A new research analysis from Frost & Sullivan, Global Pharmaceutical Contract Manufacturing Market, contends that CMOs earned revenue of $13.4 billion in 2012 and projects that the industry will reach $18.5 billion in 2017, an compound annual growth rate of 5.5%. The report covers solid dose, liquid and semi-solid dose, and injectable dose formulations. According to F&S, cost benefits and pharma companies’ desire to focus on their core competencies has created an increasing need f...